News
Current position:Product Center > Antibodies > Biosimilar Antibodies > Anti-CD3×CD20 hIgG1 Bispecific Antibody (Epcobio)
Anti-CD3×CD20 hIgG1 Bispecific Antibody (Epcobio)
基本信息
Get A Quote

Cat.No:GM-88130MAB

Product:Anti-CD3×CD20 hIgG1 Bispecific Antibody (Epcobio)



Cat. No. & Size
Get A Quote

GM-88130MAB-1mg / 1 mg

GM-88130MAB-5mg / 5 mg

GM-88130MAB-25mg / 5 mg * 5 vials

GM-88130MAB-50mg / 50 mg

GM-88130MAB-100mg / 50 mg * 2 vials



Description
Get A Quote

Expression System

CHO

Aggregation

< 5% as determined by SEC-HPLC

Purity

> 95% as determined by SDS-PAGE

Endotoxin

< 1 EU/mg, determined by LAL gel clotting assay

Sterility

0.2 μm Filtered

Target

CD3&CD20

Clone

Epcoritamab

Alternative Names

CD3: ALPS5,CD,CD152,CELIAC3,CTLA-4,GRD4, GSE, IDDM12

CD20: CD279, PD-1, PDCD1, SLEB2, hPD-1, hPD-l, hSLE1

Source/Isotype

Human IgG1 K214R/L234F/L235E/D265A /D356E/L358M/delta447K kappa;

Human IgG1 K214R/L234F/L235E/D265A/D356E/L358M/delta447K lambda2

Application

Activation assay

Description

Epcoritamab (also known as EP-C1 or ABBV-181) is a novel bispecific antibody that primarily targets the B cell surface antigens CD3 and CD20. By bringing T cells and tumor cells together, it facilitates the activation of T cells and enhances the anti-tumor immune response.

Formulation

phosphate-buffered solution, pH 7.2-7.4.



Data
Get A Quote

image.png

image.png

image.png


Message Consultation
If you have more questions, please fill in the relevant information,we'll respond as soon as possible to assist you!
Reset
Submit
You can also contact us on the Scientist and Science Exchange marketplaces.
Current position:Product Center > -- > Anti-CD3×CD20 hIgG1 Bispecific Antibody (Epcobio)
classify
Anti-CD3×CD20 hIgG1 Bispecific Antibody (Epcobio)
基本信息
Get A Quote

Cat.No:GM-88130MAB

Product:Anti-CD3×CD20 hIgG1 Bispecific Antibody (Epcobio)



Cat. No. & Size
Get A Quote

GM-88130MAB-1mg / 1 mg

GM-88130MAB-5mg / 5 mg

GM-88130MAB-25mg / 5 mg * 5 vials

GM-88130MAB-50mg / 50 mg

GM-88130MAB-100mg / 50 mg * 2 vials



Description
Get A Quote

Expression System

CHO

Aggregation

< 5% as determined by SEC-HPLC

Purity

> 95% as determined by SDS-PAGE

Endotoxin

< 1 EU/mg, determined by LAL gel clotting assay

Sterility

0.2 μm Filtered

Target

CD3&CD20

Clone

Epcoritamab

Alternative Names

CD3: ALPS5,CD,CD152,CELIAC3,CTLA-4,GRD4, GSE, IDDM12

CD20: CD279, PD-1, PDCD1, SLEB2, hPD-1, hPD-l, hSLE1

Source/Isotype

Human IgG1 K214R/L234F/L235E/D265A /D356E/L358M/delta447K kappa;

Human IgG1 K214R/L234F/L235E/D265A/D356E/L358M/delta447K lambda2

Application

Activation assay

Description

Epcoritamab (also known as EP-C1 or ABBV-181) is a novel bispecific antibody that primarily targets the B cell surface antigens CD3 and CD20. By bringing T cells and tumor cells together, it facilitates the activation of T cells and enhances the anti-tumor immune response.

Formulation

phosphate-buffered solution, pH 7.2-7.4.



Data
Get A Quote

image.png

image.png

image.png


Message Consultation
If you have more questions, please fill in the relevant information,we'll respond as soon as possible to assist you!
Reset
Submit
You can also contact us on the Scientist and Science Exchange marketplaces.
Message consultation
reset
submit
Service
Message
Message consultation
reset
submit